Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.18 +6.86%
Revenue Growth %: -78.9%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: -78.9%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Societe Generale SA (GLE:FP) (SCGLY) PT Raised to EUR83 at JPMorgan
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
